Clinical Study

Debio1143-Scchn-301- A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study Of Debio 1143 In Combination With Platinum-Based Chemotherapy And Standard Fractionation Intensity-Modulated Radiotherapy In Patients With Locally Advanced Squamous Cell Car

Posted Date: May 5, 2021

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The primary objective of the study is to demonstrate superior efficacy of Debio 1143 vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck. Efficacy will be determined by measuring Event Free survival.


Histologically Confirmed Diagnosis In Previously Untreated Locally Advanced Squamous Cell Carcinoma Of The Head And Neck, Ecog 0-1, Peripheral Neuropathy < Grade 2, Adequate Hematologic, Renal And Hepatic Function, No Primary Tumor Of Nasopharyngeal, Paranasal Sinuses, Nasal Or Oral Cavity, Salivary, Thyroid Or Parathyroid Gland Pathologies, Skin Or Unknown Primary Site, No Metastatic Disease, No Prior Definitive Or Adjuvant Radiotherapy (Rt) And/Or Radical Surgery To The Head And Neck Region Which May Jeopardize The Primary Tumor Irradiation Plan,


Hnscc, Head And Neck Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.